Formulation and In Vitro Evaluation of Polymer-Based Fluvoxamine Nanoemulsion
Fuente:
Zenodo
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Recurso digital |
| Publicado: |
Zenodo
2025
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1866901765016780800 |
|---|---|
| author | Obed Mihriemate, Md. Zulphikar Ali* |
| author_facet | Obed Mihriemate, Md. Zulphikar Ali* |
| contents | <p><span lang="EN-US">Background: Fluvoxamine is an antidepressant that often faces challenges related to its bioavailability and stability. Enhancing its delivery through innovative formulations can significantly improve therapeutic outcomes for patients suffering from depression. Objective: The primary aim of this study was to formulate and evaluate a polymer-based nanoemulsion of Fluvoxamine, focusing on improving its bioavailability and stability. Approach: The study involved the development of a nanoemulsion using various polymers and surfactants. The formulation parameters were optimized through systematic experimentation. In vitro evaluations were conducted to assess the physicochemical properties, including droplet size, stability, and drug release profiles. Results: The optimized formulation, referred to as F7, demonstrated a significant enhancement in Fluvoxamine's solubility and stability compared to conventional formulations. The in vitro release studies indicated a sustained release profile, which is crucial for maintaining therapeutic levels of the drug over an extended period. Discussion: The findings suggest that the polymer-based nanoemulsion could potentially improve the bioavailability of Fluvoxamine, thereby enhancing its therapeutic efficacy in treating depression. Future research is recommended to further optimize the formulation parameters, explore scalability for large-scale production, and conduct pre-clinical and clinical studies to assess long-term efficacy and safety profiles. If successfully translated into clinical practice, the F7 formulation has the potential to considerably enhance therapy outcomes for depression patients, ultimately improving their quality of life</span><span lang="EN-US">. </span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_15183617 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Formulation and In Vitro Evaluation of Polymer-Based Fluvoxamine Nanoemulsion Obed Mihriemate, Md. Zulphikar Ali* Fluvoxamine, Nanoemulsion, Polymer – based, Entrapment Efficiency, In Vitro Evaluation <p><span lang="EN-US">Background: Fluvoxamine is an antidepressant that often faces challenges related to its bioavailability and stability. Enhancing its delivery through innovative formulations can significantly improve therapeutic outcomes for patients suffering from depression. Objective: The primary aim of this study was to formulate and evaluate a polymer-based nanoemulsion of Fluvoxamine, focusing on improving its bioavailability and stability. Approach: The study involved the development of a nanoemulsion using various polymers and surfactants. The formulation parameters were optimized through systematic experimentation. In vitro evaluations were conducted to assess the physicochemical properties, including droplet size, stability, and drug release profiles. Results: The optimized formulation, referred to as F7, demonstrated a significant enhancement in Fluvoxamine's solubility and stability compared to conventional formulations. The in vitro release studies indicated a sustained release profile, which is crucial for maintaining therapeutic levels of the drug over an extended period. Discussion: The findings suggest that the polymer-based nanoemulsion could potentially improve the bioavailability of Fluvoxamine, thereby enhancing its therapeutic efficacy in treating depression. Future research is recommended to further optimize the formulation parameters, explore scalability for large-scale production, and conduct pre-clinical and clinical studies to assess long-term efficacy and safety profiles. If successfully translated into clinical practice, the F7 formulation has the potential to considerably enhance therapy outcomes for depression patients, ultimately improving their quality of life</span><span lang="EN-US">. </span></p> |
| title | Formulation and In Vitro Evaluation of Polymer-Based Fluvoxamine Nanoemulsion |
| topic | Fluvoxamine, Nanoemulsion, Polymer – based, Entrapment Efficiency, In Vitro Evaluation |
| url | https://doi.org/10.5281/zenodo.15183617 |